This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burrage, M.
Right arrow Articles by Miller, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burrage, M.
Right arrow Articles by Miller, E.

 Previous Article  |  Next Article 

Infection and Immunity, September 2002, p. 4946-4954, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4946-4954.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Effect of Vaccination with Carrier Protein on Response to Meningococcal C Conjugate Vaccines and Value of Different Immunoassays as Predictors of Protection

Moya Burrage,1 Andrew Robinson,1 Ray Borrow,2 Nick Andrews,3 Joanna Southern,3 Jamie Findlow,2 Sarah Martin,2 Carol Thornton,1 David Goldblatt,4 Michael Corbel,5 Dorothea Sesardic,5 Keith Cartwight,6 Peter Richmond,3 and Elizabeth Miller3*

Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire,1 PHLS Meningococcal Reference Unit, Withington Hospital, Manchester,2 Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service,3 Immunobiology Unit, Institute of Child Health, London,4 National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire,5 Gloucester Vaccine Evaluation Unit, Public Health Laboratory, Gloucestershire Royal Hospital, Gloucester, United Kingdom6

Received 26 December 2001/ Returned for modification 15 March 2002/ Accepted 29 May 2002

In order to plan for the wide-scale introduction of meningococcal C conjugate (MCC) vaccine for United Kingdom children up to 18 years old, phase II trials were undertaken to investigate whether there was any interaction between MCC vaccines conjugated to tetanus toxoid (TT) or a derivative of diphtheria toxin (CRM197) and diphtheria-tetanus vaccines given for boosting at school entry or leaving. Children (n = 1,766) received a diphtheria-tetanus booster either 1 month before, 1 month after, or concurrently with one of three MCC vaccines conjugated to CRM197 or TT. All of the MCC vaccines induced high antibody responses to the serogroup C polysaccharide that were indicative of protection. The immune response to the MCC-TT vaccine was reduced as a result of prior immunization with a tetanus-containing vaccine, but antibody levels were still well above the lower threshold for protection. Prior or simultaneous administration of a diphtheria-containing vaccine did not affect the response to MCC-CRM197 vaccines. The immune responses to the carrier proteins were similar to those induced by a comparable dose of diphtheria or tetanus vaccine. The results also demonstrate that, for these conjugate vaccines in these age groups, both standard enzyme-linked immunosorbent assays and those that measure high-avidity antibodies to meningococcal C polysaccharide correlated equally well with assays that measure serum bactericidal antibodies, the established serological correlate of protection for MCC vaccines.

* Corresponding author. Mailing address: Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, 61 Colindale Ave., London NW9 5EQ, United Kingdom. Phone: 44 0 181 200 6868. Fax: 44 0 181 200 7868. E-mail: Emiller{at}phls.org.uk.

Editor: J. D. Clements

Infection and Immunity, September 2002, p. 4946-4954, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4946-4954.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yang, H.-H., Mascuch, S. J., Madoff, L. C., Paoletti, L. C. (2008). Recombinant Group B Streptococcus Alpha-Like Protein 3 Is an Effective Immunogen and Carrier Protein. CVI 15: 1035-1041 [Abstract] [Full Text]  
  • Snape, M D, Kelly, D F, Lewis, S, Banner, C, Kibwana, L, Moore, C E, Diggle, L, John, T, Yu, L M, Borrow, R, Borkowski, A, Nau, C, Pollard, A J (2008). Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336: 1487-1491 [Abstract] [Full Text]  
  • Fusco, P. C., Farley, E. K., Huang, C.-H., Moore, S., Michon, F. (2007). Protective Meningococcal Capsular Polysaccharide Epitopes and the Role of O Acetylation. CVI 14: 577-584 [Abstract] [Full Text]  
  • Harris, S. L., Tsao, H., Ashton, L., Goldblatt, D., Fernsten, P. (2007). Avidity of the Immunoglobulin G Response to a Neisseria meningitidis Group C Polysaccharide Conjugate Vaccine as Measured by Inhibition and Chaotropic Enzyme-Linked Immunosorbent Assays. CVI 14: 397-403 [Abstract] [Full Text]  
  • Tsai, T. F., Borrow, R., Gnehm, H. E., Vaudaux, B., Heininger, U., Desgrandchamps, D., Aebi, C., Balmer, P., Pedersen, R. D., Fritzell, B., Siegrist, C.-A. (2006). Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?. CVI 13: 854-861 [Abstract] [Full Text]  
  • Baraldo, K., Mori, E., Bartoloni, A., Norelli, F., Grandi, G., Rappuoli, R., Finco, O., Del Giudice, G. (2005). Combined Conjugate Vaccines: Enhanced Immunogenicity with the N19 Polyepitope as a Carrier Protein. Infect. Immun. 73: 5835-5841 [Abstract] [Full Text]  
  • Buttery, J. P., Riddell, A., McVernon, J., Chantler, T., Lane, L., Bowen-Morris, J., Diggle, L., Morris, R., Harnden, A., Lockhart, S., Pollard, A. J., Cartwright, K., Moxon, E. R. (2005). Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial. JAMA 293: 1751-1758 [Abstract] [Full Text]  
  • Borrow, R., Goldblatt, D., Finn, A., Southern, J., Ashton, L., Andrews, N., Lal, G., Riley, C., Rahim, R., Cartwright, K., Allan, G., Miller, E. (2003). Immunogenicity of, and Immunologic Memory to, a Reduced Primary Schedule of Meningococcal C-Tetanus Toxoid Conjugate Vaccine in Infants in the United Kingdom. Infect. Immun. 71: 5549-5555 [Abstract] [Full Text]  
  • Andrews, N., Borrow, R., Miller, E. (2003). Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England. CVI 10: 780-786 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»